Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Microbix Biosystems has received a patent from the Intellectual Property Office of the People's Republic of China for its Virusmax technology which enables egg-based vaccine manufacturers to increase the amount of influenza vaccine they produce each year.
Subscribe to our email newsletter
Virusmax has enormous implications for protecting more of the world’s population during a pandemic. The entire annual global flu vaccine production capacity is currently only about 350 million doses. Virusmax can enable manufacturers to at least double the amount of influenza vaccine they produce, reducing dependence on imported supplies.
William Gastle, CEO of Microbix, said: “China is one of the largest countries in the world that does not have domestic manufacturing capacity to supply its population with seasonal and pandemic influenza vaccine and would benefit from having access to this technology.”